On the other hand, preclinical studies have demonstrated that TIGIT blockade enhances anti-tumor T cell responses, reduces tumor growth, and restores CD8+ T cell potency, particularly when combined with PD-1 or PD-L1 inhibitors [296–298]. The gene discussed is PDCD1; the disease is neoplasm.